Video
Author(s):
A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
Unveiling the Future of Oncology: Specialized Teams at Florida Cancer Specialists & Research Institute Target Advanced Cancer Treatments
Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
Neoadjuvant Nivolumab/Ipilimumab New Standard of Care for Stage III Melanoma
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
Up to 10 Years of Follow-Up Uphold Survival Benefit With Adjuvant Dabrafenib/Trametinib in Stage III Melanoma
AI Support Tool Demonstrates Detection Utility for Melanoma at Primary Care Practices
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma
Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer
Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC
Dr Hughes on Efficacy Data for Asciminib in Newly Diagnosed Ph+ CP-CML